222 related articles for article (PubMed ID: 18393806)
1. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease.
Nalivaeva NN; Fisk LR; Belyaev ND; Turner AJ
Curr Alzheimer Res; 2008 Apr; 5(2):212-24. PubMed ID: 18393806
[TBL] [Abstract][Full Text] [Related]
2. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?
Carson JA; Turner AJ
J Neurochem; 2002 Apr; 81(1):1-8. PubMed ID: 12067222
[TBL] [Abstract][Full Text] [Related]
3. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme.
Eckman EA; Adams SK; Troendle FJ; Stodola BA; Kahn MA; Fauq AH; Xiao HD; Bernstein KE; Eckman CB
J Biol Chem; 2006 Oct; 281(41):30471-8. PubMed ID: 16912050
[TBL] [Abstract][Full Text] [Related]
4. Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration.
Turner AJ; Fisk L; Nalivaeva NN
Ann N Y Acad Sci; 2004 Dec; 1035():1-20. PubMed ID: 15681797
[TBL] [Abstract][Full Text] [Related]
5. Regulation of amyloid beta-peptide levels by enzymatic degradation.
Mukherjee A; Hersh LB
J Alzheimers Dis; 2002 Oct; 4(5):341-8. PubMed ID: 12446966
[TBL] [Abstract][Full Text] [Related]
6. Effect of Global Brain Ischemia on Amyloid Precursor Protein Metabolism and Expression of Amyloid-Degrading Enzymes in Rat Cortex: Role in Pathogenesis of Alzheimer's Disease.
Babusikova E; Dobrota D; Turner AJ; Nalivaeva NN
Biochemistry (Mosc); 2021 Jun; 86(6):680-692. PubMed ID: 34225591
[TBL] [Abstract][Full Text] [Related]
7. Identification of BACE2 as an avid ß-amyloid-degrading protease.
Abdul-Hay SO; Sahara T; McBride M; Kang D; Leissring MA
Mol Neurodegener; 2012 Sep; 7():46. PubMed ID: 22986058
[TBL] [Abstract][Full Text] [Related]
8. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.
Wang S; Wang R; Chen L; Bennett DA; Dickson DW; Wang DS
J Neurochem; 2010 Oct; 115(1):47-57. PubMed ID: 20663017
[TBL] [Abstract][Full Text] [Related]
9. New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection.
Turner AJ; Nalivaeva NN
Int Rev Neurobiol; 2007; 82():113-35. PubMed ID: 17678958
[TBL] [Abstract][Full Text] [Related]
10. Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease.
Pacheco-Quinto J; Herdt A; Eckman CB; Eckman EA
J Alzheimers Dis; 2013; 33 Suppl 1(0 1):S101-10. PubMed ID: 22903130
[TBL] [Abstract][Full Text] [Related]
11. Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer's Disease.
Sikanyika NL; Parkington HC; Smith AI; Kuruppu S
Neurochem Res; 2019 Jun; 44(6):1289-1296. PubMed ID: 30806879
[TBL] [Abstract][Full Text] [Related]
12. Impaired amyloid β-degrading enzymes in brain of streptozotocin-induced diabetic rats.
Liu Y; Liu L; Lu S; Wang D; Liu X; Xie L; Wang G
J Endocrinol Invest; 2011 Jan; 34(1):26-31. PubMed ID: 20414044
[TBL] [Abstract][Full Text] [Related]
13. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention.
Eckman EA; Eckman CB
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1101-5. PubMed ID: 16246055
[TBL] [Abstract][Full Text] [Related]
14. Design of Peptide Substrate for Sensitively and Specifically Detecting Two Aβ-Degrading Enzymes: Neprilysin and Angiotensin-Converting Enzyme.
Chen PT; Chen CL; Lin LT; Lo CH; Hu CJ; Chen RP; Wang SS
PLoS One; 2016; 11(4):e0153360. PubMed ID: 27096746
[TBL] [Abstract][Full Text] [Related]
15. Amyloid beta degradation: a challenging task for brain peptidases.
Morelli L; Bulloj A; Leal MC; Castaño EM
Subcell Biochem; 2005; 38():129-45. PubMed ID: 15709476
[TBL] [Abstract][Full Text] [Related]
16. New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes.
Nalivaeva NN; Belyaev ND; Turner AJ
Neurochem Res; 2016 Mar; 41(3):620-30. PubMed ID: 26376806
[TBL] [Abstract][Full Text] [Related]
17. Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme.
Miners JS; van Helmond Z; Kehoe PG; Love S
Brain Pathol; 2010 Jul; 20(4):794-802. PubMed ID: 20175776
[TBL] [Abstract][Full Text] [Related]
18. Effects of 4-hydroxy-nonenal and Amyloid-beta on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells.
Wang R; Wang S; Malter JS; Wang DS
J Alzheimers Dis; 2009; 17(3):489-501. PubMed ID: 19363254
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation?
Zou K; Michikawa M
Rev Neurosci; 2008; 19(4-5):203-12. PubMed ID: 19145983
[TBL] [Abstract][Full Text] [Related]
20. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
